Health in SEAR 65 indicators covering health for SEAR. IndicatorLatest Year10-yr change Rank Pertussis - number of reported cases 2,449 2025 down 91.8% 16th Total tetanus - number of reported cases 164 2025 down 95.7% 14th Infant mortality rate (probability of dying between birth and age 1) 23.13 2024 down 36.4% 8th Under-five mortality rate 26.66 2024 down 39.8% 8th Maternal mortality ratio 96.26 2023 down 41.6% 6th Number of deaths among adolescents 67,025 2024 down 36.8% 6th Number of deaths among children ages 5 to 9 years 57,932 2024 down 50.7% 8th Mortality rate among children ages 5 to 9 years 1.94 2024 down 46.7% 8th Population with primary reliance on polluting fuels and technologies 493.79 2023 down 48.6% 4th Population with primary reliance on clean fuels and technologies for 763.07 2023 up 178.6% 2nd Proportion of population with primary reliance on polluting fuels and 39.3% 2023 down 49.5% 6th Proportion of population with primary reliance on fuels and 37.5% 2023 down 50.0% 6th Population with primary reliance on fuels and technologies for 470.67 2023 down 49.0% 4th Prevalence of diabetes, age-standardized 21.12 2022 up 31.9% 3rd Prevalence of diabetes, crude 20.36 2022 up 40.4% 3rd Diphtheria tetanus toxoid and pertussis first-dose (DTP1) 96.0% 2025 up 4.3% 1st Measles-containing-vaccine first-dose (MCV1) immunization coverage 96.0% 2025 up 9.1% 1st New HIV infections 0.1 2025 unchanged 5th BCG immunization coverage among 1-year-olds (%) 91.0% 2025 up 2.2% 7th Mean total cholesterol, crude 4.3 2018 down 2.3% 10th Mean total cholesterol, age-standardized 4.3 2018 down 2.3% 10th Mean HDL cholesterol, crude 1.1 2018 unchanged 10th Stunting numbers among children under 5 years of age (millions) 44,289 2024 down 25.2% 7th Stunting prevalence among children under 5 years of age (%) 29.7% 2024 down 19.7% 5th Overweight prevalence among children under 5 years of age (%) 3.4% 2024 up 47.8% 18th Overweight numbers among children under 5 years of age (thousands) 4,932 2024 up 38.6% 14th Adolescent mortality rate 2.27 2021 down 35.9% 6th Incidence of tuberculosis 201 2024 down 18.3% 4th Deaths due to tuberculosis among HIV-negative people 24 2024 down 25.0% 4th Domestic private health expenditure (PVT-D) as percentage of current 46.8% 2023 down 5.4% 2nd Prevalence of HIV among adults aged 15 to 49 0.2% 2025 down 33.3% 8th Estimated number of people (all ages) living with HIV 3.60 million 2025 unchanged 6th Estimated antiretroviral therapy coverage among people living with HIV 22.0% 2025 up 69.2% 12th Hypertension among adults aged 30-79 years, prevalence, crude 30.3 2019 up 2.5% 16th Hypertension: diagnosis coverage among adults aged 30-79 with 39.0% 2019 up 30.1% 15th Hypertension: effective treatment coverage (controlled hypertension) 13.3% 2019 up 70.5% 13th Hypertension treatment coverage among adults aged 30-79 with 31.0% 2019 up 33.9% 13th Hypertension among adults aged 30-79 years, prevalence 31.17 2019 down 0.4% 10th Hypertension: diagnosis coverage among adults aged 30-79 with 39.8% 2019 up 28.4% 16th Number of new HIV infections 82,000 2025 down 36.9% 10th Births attended by skilled health personnel 90.9% 2025 up 15.1% 7th Inactivated first-dose polio vaccine (IPV1) immunization coverage 94.0% 2025 up 944.4% 2nd Low birth weight number 7,446 2020 down 19.1% 5th Concentrations of fine particulate matter 43.74 2023 down 26.2% 1st Estimated number of MDR/RR-TB incident cases 150,000 2024 unchanged 2nd Prevalence of anaemia in children aged 6-59 months 49.0% 2019 down 10.3% 5th Number of children aged 6-59 months with anaemia 83,222 2019 down 17.0% 5th Mean hemoglobin level of children aged 6-59 months 109 2019 up 1.9% 10th Hepatitis B surface antigen (HBsAg) prevalence 0.2% 2024 down 60.0% 8th Number of deaths attributed to non-communicable diseases, by type of 1.50 million 2019 up 36.8% 9th Estimated number of malaria cases 2.74 million 2024 down 66.9% 6th Number of reported cases of poliomyelitis by wild poliovirus 0 2023 — 4th Estimated number of children needing antiretroviral therapy based on 60,000 2025 down 50.0% 4th Estimated antiretroviral therapy coverage among children 11 2025 up 10.0% 12th HPV immunization coverage estimates among primary target cohort (9-14) 8.0% 2025 — 11th Smear-positive tuberculosis treatment-success rate 89.0% 2011 up 41.3% 3rd Number of indigenous P. falciparum malaria cases 272,829 2021 down 73.2% 6th Number of suspected malaria cases 121.64 million 2021 down 18.3% 4th Number of malaria positive cases by microscopy 292,126 2021 down 79.5% 8th Number of malaria suspects examined by microscopy 91.09 million 2021 down 27.5% 2nd Page 1 of 2 Next →